TACI/TNFRSF13B/CD267 (E1D1P) Rabbit mAb

Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B) and cluster of differentiation 267 (CD267), is a single-pass type III membrane receptor that is highly expressed on the surface of mature innate-like B cells, such as marginal zone and B-1 B cells in mice, and memory B cells in humans (1-3). TACI/TNFRSF13B/CD267 is also expressed on the surface of activated T cells (4), while monocytes and dendritic cells express lower levels of TACI/TNFRSF13B/CD267 primarily intracellularly (5,6). TACI/TNFRSF13B/CD267 is the receptor for soluble ligands BAFF/TNFSF13B and APRIL/TNFSF13 (7,8). Upon ligation, TACI/TNFRSF13B/CD267 recruits tumor necrosis factor receptor–associated factor (TRAF) family members and calcium signal-modulating cyclophilin ligand (CAMLG) in order to activate NFAT, NF-κB, and AP-1 transcriptional programs (9-11). TACI/TNFRSF13B/CD267 is necessary for T cell-independent type II and type I responses (1,12), negative regulation of B cell and T follicular helper cell numbers (13,14), and promotion of class switch recombination in B cells (15). Mutations and aberrant regulation of TACI/TNFRSF13B/CD267 has been associated with cancer, autoimmune diseases, and immunodeficiency disorders (16-18). Multiple isoforms produced by alternative splicing have been identified. 1.von Bülow, G.U. et al. (2000) Mamm Genome 11, 628-32. 2.Mantchev, G.T. et al. (2007) J Immunol 179, 2282-8. 3.Tsuji, S. et al. (2011) Blood 118, 5832-9. 4.Wang, H. et al. (2001) Nat Immunol 2, 632-7. 5.Chang, S.K. et al. (2006) Blood 108, 2687-94. 6.Chang, S.K. et al. (2008) J Immunol 180, 7394-403. 7.Wu, Y. et al. (2000) J Biol Chem 275, 35478-85. 8.Yu, G. et al. (2000) Nat Immunol 1, 252-6. 9.Hymowitz, S.G. et al. (2005) J Biol Chem 280, 7218-27. 10.Xia, X.Z. et al. (2000) J Exp Med 192, 137-43. 11.von Bülow, G.U. and Bram, R.J. (1997) Science 278, 138-41. 12.Ozcan, E. et al. (2009) J Allergy Clin Immunol 123, 1277-86.e5. 13.Seshasayee, D. et al. (2003) Immunity 18, 279-88. 14.Ou, X. et al. (2012) Proc Natl Acad Sci U S A 109, 15401-6. 15.He, B. et al. (2010) Nat Immunol 11, 836-45. 16.Castigli, E. et al. (2005) Nat Genet 37, 829-34. 17.Moura, R.A. et al. (2013) J Rheumatol 40, 1293-302. 18.Abo-Elfadl, M.T. et al. (2020) Cytokine 125, 154790.